Ageless Pep Academy Clinical Education · Licensed Prescribers

PMID-30694878 – Teriparatide Fracture Prevention Systematic Review

PMID-30694878 – Teriparatide Fracture Prevention Systematic Review

Defined Daily Doses of Teriparatide (PTH 1-34) in fracture prevention: a systematic review. Simpson EL, Martyn-St James M, Hamilton J, et al. Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review. J Clin Endocrinol Metab. 2019;104(5):1506-1524.

Quick Reference

Property Value
PMID 30694878
DOI 10.1210/jc.2018-02052
Year 2019
Journal Journal of Clinical Endocrinology & Metabolism
Study Type Systematic Review
Evidence Level I
Sample Multiple RCTs pooled (postmenopausal women and men with osteoporosis)
Peptide(s) Studied Teriparatide

Key Findings

  • Teriparatide was effective for prevention of vertebral fractures in postmenopausal women with osteoporosis (strong evidence)
  • Effective for prevention of overall nonvertebral fractures (moderate evidence)
  • Not effective for prevention of site-specific nonvertebral fractures at the wrist and hip individually (likely underpowered for these endpoints)
  • Vertebral fracture risk reduction was consistent across patient subgroups including those with and without prior fractures
  • Sequential therapy (teriparatide followed by antiresorptive) maintains or extends BMD gains

Study Design

Systematic review of randomized controlled trials evaluating teriparatide (PTH 1-34) for fracture prevention in osteoporosis. Searched MEDLINE, Embase, and Cochrane databases. Included RCTs with fracture as primary or secondary outcome. Quality assessment using GRADE methodology. Synthesized evidence by fracture type (vertebral, nonvertebral, hip, wrist) and patient population.

Limitations

  • Many included trials had relatively short duration (12-24 months)
  • Hip fracture analysis underpowered across all included studies
  • Heterogeneity in study populations, concomitant therapies, and fracture definitions
  • Limited data on sequential therapy regimens in included trials
  • Most evidence derived from the original Neer 2001 Fracture Prevention Trial

Clinical Relevance

This systematic review established the evidence hierarchy for teriparatide fracture prevention: strongest for vertebral fractures, moderate for nonvertebral fractures as a group, and insufficient for hip fractures specifically. This supports targeted use in patients whose primary fracture risk is vertebral (e.g., glucocorticoid users, elderly with kyphosis). The review also highlights the importance of sequential therapy planning — stopping teriparatide without transitioning to an antiresorptive leads to rapid BMD loss, emphasizing that teriparatide is part of a treatment strategy rather than a standalone therapy.

Related

#research #systematic-review #teriparatide #evidence-level-I